RxDoctor Payments Data

Rebecca Polkabla, PA

Physician Assistant · Surprise, AZNPI 1649583238

Payments from drug & device makers

$969in general payments, 2019–2025

Across 36 payments — averaging $26.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$188
  • Bayer$164
  • Amgen$136
  • AstraZeneca$116
  • Merck$77
  • Novartis$60
  • plus $230 from 7 others

What the payments were for

  • Food & beverage$969100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$969 in reported general payments places this provider in the 65th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$52,697
Medicare patients
172
Services billed
654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$70,514
JanuviaSitagliptin Phosphate35$59,340
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$50,975
EliquisApixaban35$38,017
FarxigaDapagliflozin Propanediol22$34,532
TrulicityDulaglutide20$32,388
Soliqua 100-33Insulin Glargine/Lixisenatide21$27,283
XareltoRivaroxaban14$23,876
MounjaroTirzepatide12$21,836
LinzessLinaclotide15$17,029
Janumet XrSitagliptin Phos/Metformin Hcl17$13,606
VascepaIcosapent Ethyl19$8,442
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$5,065
Fenofibrate41$4,971
SymbicortBudesonide/Formoterol Fumarate14$4,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$77$72,94652 claims
Novo NordiskOzempic$15$70,51452 claims
AstraZenecaFarxiga, Symbicort$116$39,33436 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$56$27,28321 claims
Johnson & JohnsonXarelto$41$23,87614 claims
AbbVieLinzess, Synthroid$188$18,34029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →